Inhibition of smooth muscle cell migration by heme oxygenase I

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0


C435S320100, C435S458000, C514S04400A, C536S023100

Reexamination Certificate




The role of inducible second messenger gases like carbon monoxide (CO) in the pathophysiology of cardiovascular disease are not clear to date (Wever, et al.,
97,108-112, 1998; Cooke and Dzau,
96, 379-382, 1997; Moncada, et al.,
. 43, 109-142, 1997; Loscalzo, and Welch,
Progress in Cardiovascular Diseases
38, 87-104, 1995). The heme oxygenase system, that generates CO, consists of three isozymes identified so far: the inducible heme oxygenase I (HO-1), the constitutive expressed HO-2 and HO-3(Moncada, et al,
.43, 109-142, 1997; McCoubrey et al.,
247, 725-732, 1997; Maines, et al.,
. 261, 411-419, 1986; Shibahara et al.,
Proceedings of the National Academy of Sciences USA
240, 7865-7869, 1985; Rotenberg et al.,
. 265, 7501-7506, 1990), which all catalyze oxidation of heme into the biologically active molecules iron, biliverdin and CO.
The widespread expression of the heme oxygenases led to the hypothesis that the CO system may play other roles than maintaining heme homeostasis and indicate that CO may function as an important biological molecule in a second-messenger capacity. Indeed, CO has been shown to activate guanylyl cyclase by displacing the iron out of the plane of the porphoryrin ring of the heme protein. The formed cGMP then activates cGMP-dependent kinases. Recent studies now show that HO-derived carbon monoxide plays a physiological role in the regulation of local vascular smooth muscle tone and platelet function through activation of soluble guanylyl cyclase.
Hence, dysregulation of the CO system may play an eminent role in the pathogenesis of the vascular proliferative disorders, like atherosclerosis and restenosis. Smooth muscle cell proliferation and migration into the vascular lesion play a key role in the pathogenesis of these occlusive vascular proliferative disorders, which form the major delimiter to the long term success rate of percutaneous (coronary) transluminal procedures as well as of arterial and venous bypass grafting.
The physical and thrombotic events accompanying PTCA and CABG procedures result in a cascade of mitogen, chemotactic factor and inflammatory cytokine release which all promote local vascular smooth muscle cell and immune competent cell recruitment, and reentering and progression through the cell cycle. Activated medial smooth muscle cells proliferate and migrate in the damaged intima and synthesize extracellular matrix, including fibrin and collagen, leading to the (re)occlusion of the vessel. Pharmacological interventions to avert this process of aberrant vascular cell proliferation and migration has been largely unrewarding.
Thus, there exists a need for safe, effective methods of inhibiting vascular smooth muscle cell proliferation and migration into the lumen of the blood vessel following injury to the blood vessel.

patent: 6066333 (2000-05-01), Willis et al.
Morita et al. Endothelial cell expression of vasoconstrictores and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J. Clin. Invest. vol. 96:2676-2682, Dec. 1995.*
Ali et al. The use of DNA viruses as vectors for gene therapy. Gene Therapy vol. 1:367-384, Jan. 1994.*
Lee et al. Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia. PNAS vol. 93:10393-10398, Sep. 1996.*
Deramaudt et al. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J. Cell. Biochem. vol. 68:121-127, Jan. 1998.*
Orkin et al. Report and recommendations of the panel to assess teh NIH investment in research on gene therapy, Dec. 1995.*
Marshall E Gene therapy's growing pains. Science vol. 269:1050-1055, Aug. 1995.*
Verma et al. Gene therapy—promises, problems and prospects. Nature vol. 389:239-242, Sep. 1997.*
Anderson WF Human gene therapy. Nature vol. 392:25-30, Apr. 1998.*
Abraham, Nader et al., “Adenovirus-Mediated Heme Oxygenase-1 Gene Transfer Into Rabbit Ocular Tissues,”Investigative Ophthalmology&Visual Science, vol. 36, No. 11, pp. 2202-2210, Oct. 1995.
Morita, Toshisuke et al., “Carbon Monoxide Controls the Proliferation of Hypoxic Vascular Smooth Muscle Cells,”The Journal of Biological Chemistry, vol. 272, No. 52, pp. 32804-32809, Dec. 26, 1997.
Nabel, Elizabeth et al., “Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall,”Science, vol. 244, pp. 1342-1344, Jun. 16, 1989.
Nabel, Elizabeth et al., “Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall,”Science, vol. 249, pp. 1285-1288, Sep. 14, 1990.
Abraham, N.G. et al., “Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: Protective effect against heme and hemoglobin toxicity,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 6798-6802, Jul. 1995.
Duckers et al., “Protective properties of recombinant heme oxygenase 1 in vitro and in vivo in the ballon injured porcine artery,”Circulation, vol. 98, No. 17 Suppl., pp. 1739-1740, Oct. 27, 1998, Meeting Info: 71stScientific Sessions of the American Heart Association, Dallas, Texas, USA, Nov. 8-11, 1998.
Wever, Robert M.F. et al., “Atherosclerosis and the Two Faces of Endothelial Nitric Oxide Synthase,”Circulation, 97, pp. 108-112, Jan. 1998.
Cooke, John P. et al., “Derangements of the Nitric Oxide Synthase Pathway, L-Arginine, and Cardiovascular Diseases,”Circulation, vol. 96, No. 2, pp. 379-382, Jul. 15, 1997.
Moncada, S. et al., “Nitric oxide: Physiology, Pathophysiology, and Pharmacology,”Pharmacol Reviews, vol. 43, No. 2, pp. 109-142, Jun. 1991.
Loscalzo, Joseph et al., “Nitric oxide and Its Role in the Cardiovascular System,”Progress in Cardiovascular Diseases, vol. XXXVIII, No. 2, pp. 87-104, Sep./Oct. 1995.
McCoubrey, William K. et al., “Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3,”Eur.J.Biochem, 247, pp. 725-732, 1997.
Maines, Mahin D. et al., “Characterization of Two Constitutive Forms of Rat Liver Microsomal Heme Oxygenase. Only One Molecular Species of the Enzyme is Inducible,”J.Biol.Chem., vol. 261, No. 1, pp. 411-419, 1986.
Shibahara, Shigeki et al., “Cloning and expression of cDNA for rat heme oxygenase,”Proceedings of the National Academy of Sciences USA,vol. 82, pp. 7865-7869, Dec. 1985.
Rotenberg, Mitch et al., “Isolation, Characterization, and Expression inEscherichia coliof a cDNA Encoding Rat Heme Oxygenase-2,”J.Biol.Chem., vol. 265, No. 13, pp. 7501-7506, May 5, 1990.
Yoshida, Tadashi et al., “Human heme oxygenase cDNA and induction of its mRNA by hemin,”Eur. J. Biochem., 171, pp. 457-461, Feb. 1988.


Say what you really think

Search for the USA inventors and patents. Rate them and share your experience with other people.


Inhibition of smooth muscle cell migration by heme oxygenase I does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of smooth muscle cell migration by heme oxygenase I, we encourage you to share that experience with our community. Your opinion is very important and Inhibition of smooth muscle cell migration by heme oxygenase I will most certainly appreciate the feedback.

Rate now


Profile ID: LFUS-PAI-O-2489484

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.